A translational medicine program includes the adoption of biomarkers to mitigate Phase I and II clinical risks, identify patient subpopulations, facilitate decision-making, and accelerate the release of a drug on the market.

BBCR’s epigenetic expert, Dr. Claudio Carini, has been a pioneer in epigenetics leading the effort of major pharmaceutical companies.

BBCR helps to bridge the gap between pre-clinical and early clinical development. Translational medicine is a bridge between pre-clinical and early clinical development (from bench to bedside), creating the foundation for precision medicine in late clinical development. A translational medicine program includes the adoption of biomarkers to mitigate clinical trial risk, identify patient subpopulations, facilitate decision-making, and accelerate drugs’ market approval.

Contact Us Today to Learn More

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.

"*" indicates required fields

NAME:*

EMAIL:*

PHONE NUMBER:

COMMENTS:*

CAPTCHA

Comments

This field is for validation purposes and should be left unchanged.